ÐßÐßÊÓÆµ Announces Oversubscribed $115 Million Series D Financing to Accelerate Clinical Programs in Indications of High Unmet Need 17 November 2025 | Press release
ÐßÐßÊÓÆµ Announces Phase 1/2a Data for DNA Polymerase Theta Inhibitor ART6043 at ESMO Congress 2025 17 October 2025 | Press release
ÐßÐßÊÓÆµ to Announce First Phase 1/2a Data for DNA Polymerase Theta (Polθ) Inhibitor ART6043 in Advanced Solid Tumors in Oral Presentation at ESMO 13 October 2025 | Press release
ÐßÐßÊÓÆµ Receives U.S. FDA Fast Track Designation for alnodesertib in ATM-negative Metastatic Colorectal Cancer (mCRC) 24 September 2025 | Press release
ÐßÐßÊÓÆµ Appoints Michael T. Andriole as CEO and Director to Advance Alnodesertib (ART0380) into Late-stage Development 12 August 2025 | Press release
ÐßÐßÊÓÆµ Reports Differentiated Clinical Activity in STELLA Phase 1/2a Study for Lead Program ART0380 at the American Association for Cancer Research (AACR) Annual Meeting 2025 29 April 2025 | Press release
ÐßÐßÊÓÆµ Announces Details of Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025 15 April 2025 | Press release
ÐßÐßÊÓÆµ to Present at the 43rd Annual J.P. Morgan Healthcare Conference 19 December 2024 | Press release